These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
565 related articles for article (PubMed ID: 18040043)
21. S1, a novel pan-BH3 mimetic, induces apoptosis in Mcl-1-overexpressing cells through Bak. Song T; Chang X; Zhang Z; Liu Y; Shen X J Pharmacol Sci; 2012; 119(4):330-40. PubMed ID: 22814102 [TBL] [Abstract][Full Text] [Related]
22. BH3 mimetic ABT-737 and a proteasome inhibitor synergistically kill melanomas through Noxa-dependent apoptosis. Miller LA; Goldstein NB; Johannes WU; Walton CH; Fujita M; Norris DA; Shellman YG J Invest Dermatol; 2009 Apr; 129(4):964-71. PubMed ID: 18987671 [TBL] [Abstract][Full Text] [Related]
23. Bcl-2 family proteins contribute to apoptotic resistance in lung cancer multicellular spheroids. Yang TM; Barbone D; Fennell DA; Broaddus VC Am J Respir Cell Mol Biol; 2009 Jul; 41(1):14-23. PubMed ID: 19097992 [TBL] [Abstract][Full Text] [Related]
24. A novel BH3 mimetic efficiently induces apoptosis in melanoma cells through direct binding to anti-apoptotic Bcl-2 family proteins, including phosphorylated Mcl-1. Liu Y; Xie M; Song T; Sheng H; Yu X; Zhang Z Pigment Cell Melanoma Res; 2015 Mar; 28(2):161-70. PubMed ID: 25324174 [TBL] [Abstract][Full Text] [Related]
25. Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia. Pan R; Ruvolo VR; Wei J; Konopleva M; Reed JC; Pellecchia M; Andreeff M; Ruvolo PP Blood; 2015 Jul; 126(3):363-72. PubMed ID: 26045609 [TBL] [Abstract][Full Text] [Related]
26. MCL-1 is the key target of adjuvant chemotherapy to reverse the cisplatin-resistance in NSCLC. Ma J; Zhao Z; Wu K; Xu Z; Liu K Gene; 2016 Aug; 587(2):147-54. PubMed ID: 27138804 [TBL] [Abstract][Full Text] [Related]
27. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice. Anstee NS; Bilardi RA; Ng AP; Xu Z; Robati M; Vandenberg CJ; Cory S Cell Death Differ; 2019 Jul; 26(7):1316-1331. PubMed ID: 30470795 [TBL] [Abstract][Full Text] [Related]
28. Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process. Rahmani M; Aust MM; Attkisson E; Williams DC; Ferreira-Gonzalez A; Grant S Blood; 2012 Jun; 119(25):6089-98. PubMed ID: 22446485 [TBL] [Abstract][Full Text] [Related]
29. MDM2 antagonist Nutlin-3 enhances bortezomib-mediated mitochondrial apoptosis in TP53-mutated mantle cell lymphoma. Jin L; Tabe Y; Kojima K; Zhou Y; Pittaluga S; Konopleva M; Miida T; Raffeld M Cancer Lett; 2010 Dec; 299(2):161-70. PubMed ID: 20850924 [TBL] [Abstract][Full Text] [Related]
30. BAK and NOXA are critical determinants of mitochondrial apoptosis induced by bortezomib in mesothelioma. Busacca S; Chacko AD; Klabatsa A; Arthur K; Sheaff M; Barbone D; Mutti L; Gunasekharan VK; Gorski JJ; El-Tanani M; Broaddus VC; Gaudino G; Fennell DA PLoS One; 2013; 8(6):e65489. PubMed ID: 23762382 [TBL] [Abstract][Full Text] [Related]
31. Clitocine induces apoptosis and enhances the lethality of ABT-737 in human colon cancer cells by disrupting the interaction of Mcl-1 and Bak. Sun JG; Xiang J; Zeng XL; Li X; Wu P; Fung KP; Liu FY Cancer Lett; 2014 Dec; 355(2):253-63. PubMed ID: 25304383 [TBL] [Abstract][Full Text] [Related]
32. CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies. Chen S; Dai Y; Pei XY; Myers J; Wang L; Kramer LB; Garnett M; Schwartz DM; Su F; Simmons GL; Richey JD; Larsen DG; Dent P; Orlowski RZ; Grant S Cancer Res; 2012 Aug; 72(16):4225-37. PubMed ID: 22693249 [TBL] [Abstract][Full Text] [Related]
33. VSV oncolysis in combination with the BCL-2 inhibitor obatoclax overcomes apoptosis resistance in chronic lymphocytic leukemia. Samuel S; Tumilasci VF; Oliere S; Nguyên TL; Shamy A; Bell J; Hiscott J Mol Ther; 2010 Dec; 18(12):2094-103. PubMed ID: 20842105 [TBL] [Abstract][Full Text] [Related]
34. Obatoclax induces Atg7-dependent autophagy independent of beclin-1 and BAX/BAK. McCoy F; Hurwitz J; McTavish N; Paul I; Barnes C; O'Hagan B; Odrzywol K; Murray J; Longley D; McKerr G; Fennell DA Cell Death Dis; 2010 Dec; 1(12):e108. PubMed ID: 21368880 [TBL] [Abstract][Full Text] [Related]
35. Platinum resistant cancer cells conserve sensitivity to BH3 domains and obatoclax induced mitochondrial apoptosis. Crawford N; Chacko AD; Savage KI; McCoy F; Redmond K; Longley DB; Fennell DA Apoptosis; 2011 Mar; 16(3):311-20. PubMed ID: 21107700 [TBL] [Abstract][Full Text] [Related]
36. Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myeloma. Trudel S; Li ZH; Rauw J; Tiedemann RE; Wen XY; Stewart AK Blood; 2007 Jun; 109(12):5430-8. PubMed ID: 17332241 [TBL] [Abstract][Full Text] [Related]
37. Noxa/Bcl-2 protein interactions contribute to bortezomib resistance in human lymphoid cells. Smith AJ; Dai H; Correia C; Takahashi R; Lee SH; Schmitz I; Kaufmann SH J Biol Chem; 2011 May; 286(20):17682-92. PubMed ID: 21454712 [TBL] [Abstract][Full Text] [Related]
38. Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma. Chiron D; Dousset C; Brosseau C; Touzeau C; Maïga S; Moreau P; Pellat-Deceunynck C; Le Gouill S; Amiot M Oncotarget; 2015 Apr; 6(11):8750-9. PubMed ID: 25797245 [TBL] [Abstract][Full Text] [Related]
39. The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies. Paoluzzi L; Gonen M; Bhagat G; Furman RR; Gardner JR; Scotto L; Gueorguiev VD; Heaney ML; Manova K; O'Connor OA Blood; 2008 Oct; 112(7):2906-16. PubMed ID: 18591385 [TBL] [Abstract][Full Text] [Related]
40. A novel BH3 mimetic S1 potently induces Bax/Bak-dependent apoptosis by targeting both Bcl-2 and Mcl-1. Zhang Z; Song T; Zhang T; Gao J; Wu G; An L; Du G Int J Cancer; 2011 Apr; 128(7):1724-35. PubMed ID: 20503275 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]